Distinguished in Eosinophilic Asthma

Konstantinos Kostikas

Stavrou Niarchou Avenue, 
Ioannina, ESYE21, GR 
Distinguished in Eosinophilic Asthma
Stavrou Niarchou Avenue, 
Ioannina, ESYE21, GR 
OverviewLocationsClinical Research

Overview

Konstantinos Kostikas practices in Ioannina, Greece. Mr. Kostikas is rated as a Distinguished expert by MediFind in the treatment of Eosinophilic Asthma. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Asthma, Eosinophilic Asthma, and Pulmonary Embolism.

His clinical research consists of co-authoring 252 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Eosinophilic Asthma.

Gender
Male

Locations

Stavrou Niarchou Avenue, Ioannina, ESYE21 45500, Greece

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
Enrollment Status: Terminated
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drug: HZN-825
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
View 1 Less Clinical Trial

252 Total Publications

Reply to Liu et al., Zhou et al., and Dong et al.
Reply to Liu et al., Zhou et al., and Dong et al.
Journal: American journal of respiratory and critical care medicine
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kostikas's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile